来氟米特治疗风湿免疫性疾病的临床效果分析
|
摘要
目的观察分析来氟米特治疗风湿免疫性疾病的临床效果。方法选取本院2017年8月至2018年8月收治的90例风湿免疫性疾病患者,按照不同治疗方法分为对照组(应用激素治疗方法)和实验组(在对照组基础上应用来氟米特治疗方法),每组45例。采用统计学分析两组风湿免疫性疾病患者的临床总有效率、临床指标(平均正常活动时间、平均关节压痛消失时间以及平均关节肿胀消失时间)、不良反应发生率(脱发、肝肾功能损害以及肠胃功能损害)以及治疗前后血沉水平、超敏C反应蛋白水平、平均晨僵时间。结果实验组患者的临床总有效率显著高于对照组(P<0.05),实验组患者各项临床指标显著优于对照组(P<0.05),两组患者的脱发、肝肾功能损害以及肠胃功能损害等不良反应发生率比较差异无统计学意义;两组患者治疗前血沉水平、超敏C反应蛋白水平、平均晨僵时间比较差异无统计学意义,治疗后实验组患者的血沉水平、超敏C反应蛋白水平、平均晨僵时间显著优于对照组(P<0.05)。结论来氟米特治疗风湿免疫性疾病的临床效果较为理想。
Objective To observe the clinical effect of leflunomide in the treatment of rheumatic immune diseases. Methods 90 patients with rheumatic immune diseases admitted to our hospital(August 2017 to August 2018) were divided into the control group(using hormone therapy) and the experimental group(based on the control group) according to different treatment methods. Application of leflunomide treatment), 45 cases in each group. Statistical analysis of the total clinical effective rate, clinical indicators(mean normal activity time, mean joint tenderness disappearance time and average joint swelling disappearance time), adverse reaction rate(alopecia, liver and kidney dysfunction) Gastrointestinal dysfunction) and erythrocyte sedimentation level, high-sensitivity C-reactive protein levels, and mean morning stiffness time before and after treatment. Results The total clinical effective rate of patients with rheumatic immune disease was significantly higher than that of the control group(P<0.05). The clinical indexes of rheumatoid immune disease patients in the experimental group were significantly better than those in the control group(P<0.05). The incidence of adverse reactions such as alopecia, liver and kidney dysfunction and gastrointestinal dysfunction in patients with sexually transmitted diseases was not statistically significant; pre-treatment erythrocyte sedimentation level, high-sensitivity C-reactive protein levels, average in two groups of patients with rheumatic immune diseases The morning stiffness time was not statistically significant. After treatment, the erythrocyte sedimentation level, high-sensitivity C-reactive protein level and mean morning stiffness time of the experimental group were significantly better than those of the control group(P<0.05). Conclusion The clinical effect of leflunomide in the treatment of rheumatic immune diseases is ideal.
Objective To observe the clinical effect of leflunomide in the treatment of rheumatic immune diseases. Methods 90 patients with rheumatic immune diseases admitted to our hospital(August 2017 to August 2018) were divided into the control group(using hormone therapy) and the experimental group(based on the control group) according to different treatment methods. Application of leflunomide treatment), 45 cases in each group. Statistical analysis of the total clinical effective rate, clinical indicators(mean normal activity time, mean joint tenderness disappearance time and average joint swelling disappearance time), adverse reaction rate(alopecia, liver and kidney dysfunction) Gastrointestinal dysfunction) and erythrocyte sedimentation level, high-sensitivity C-reactive protein levels, and mean morning stiffness time before and after treatment. Results The total clinical effective rate of patients with rheumatic immune disease was significantly higher than that of the control group(P<0.05). The clinical indexes of rheumatoid immune disease patients in the experimental group were significantly better than those in the control group(P<0.05). The incidence of adverse reactions such as alopecia, liver and kidney dysfunction and gastrointestinal dysfunction in patients with sexually transmitted diseases was not statistically significant; pre-treatment erythrocyte sedimentation level, high-sensitivity C-reactive protein levels, average in two groups of patients with rheumatic immune diseases The morning stiffness time was not statistically significant. After treatment, the erythrocyte sedimentation level, high-sensitivity C-reactive protein level and mean morning stiffness time of the experimental group were significantly better than those of the control group(P<0.05). Conclusion The clinical effect of leflunomide in the treatment of rheumatic immune diseases is ideal.
引文
[1]吕鸿,刘月侠,徐扬,等.激素联合来氟米特、环磷酰胺治疗狼疮肾炎疗效观察[J].河北医药,2014,18(10):1540-1541.
[2]何奕坤,杨光辉,郑琪,等.艾拉莫德治疗类风湿关节炎合并肺间质病变的临床观察[J].实用临床医药杂志,2015,19(23):152-154.
[3]杨有芹,常晓东,程茂丽,等.来氟米特联合糖皮质激素治疗进展性IgA肾病的疗效及对VCAM-1水平的影响[J].现代生物医学进展,2016,16(11):2134-2137.
[4]席海英,霍月红,雷鹏程,等.缓解病情抗风湿药联合治疗难治性银屑病的前瞻性研究[J].中国药物与临床,2014,14(9):1271-1273.
[5]崔轶霞,杨宁.雷公藤多甙联合来氟米特治疗对老年活动性类风湿关节炎患者C反应蛋白、白细胞介素-10、可溶性细胞黏附分子1水平的影响[J].中国老年学杂志,2016,36(19):4878-4880.
[6]周平.甲氨蝶呤联合来氟米特治疗类风湿关节炎患者临床疗效及安全性[J].中国老年学杂志,2014,14(20):5717-5718.
[7]饶慧,肖嫦娟,曾清华,等.来氟米特联合糖皮质激素治疗系统性红斑狼疮的临床疗效及对血清IL-8和IL-10水平的影响[J].中国老年学杂志,2015,35(23):6874-6876.
[8]姜一真,唐若余,潘娇娇,等.泼尼松联合甲氨蝶呤或来氟米特治疗老年类风湿关节炎的疗效比较[J].中国老年学杂志,2015,19(21):6199-6201.
[2]何奕坤,杨光辉,郑琪,等.艾拉莫德治疗类风湿关节炎合并肺间质病变的临床观察[J].实用临床医药杂志,2015,19(23):152-154.
[3]杨有芹,常晓东,程茂丽,等.来氟米特联合糖皮质激素治疗进展性IgA肾病的疗效及对VCAM-1水平的影响[J].现代生物医学进展,2016,16(11):2134-2137.
[4]席海英,霍月红,雷鹏程,等.缓解病情抗风湿药联合治疗难治性银屑病的前瞻性研究[J].中国药物与临床,2014,14(9):1271-1273.
[5]崔轶霞,杨宁.雷公藤多甙联合来氟米特治疗对老年活动性类风湿关节炎患者C反应蛋白、白细胞介素-10、可溶性细胞黏附分子1水平的影响[J].中国老年学杂志,2016,36(19):4878-4880.
[6]周平.甲氨蝶呤联合来氟米特治疗类风湿关节炎患者临床疗效及安全性[J].中国老年学杂志,2014,14(20):5717-5718.
[7]饶慧,肖嫦娟,曾清华,等.来氟米特联合糖皮质激素治疗系统性红斑狼疮的临床疗效及对血清IL-8和IL-10水平的影响[J].中国老年学杂志,2015,35(23):6874-6876.
[8]姜一真,唐若余,潘娇娇,等.泼尼松联合甲氨蝶呤或来氟米特治疗老年类风湿关节炎的疗效比较[J].中国老年学杂志,2015,19(21):6199-6201.